PTPI | tickerfilter.com

Fundamental analysis

38%

Profitability 35%

Dept financing 29%

Liquidity 50%

Performance 40%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

2.50%

1 Month

2.50%

3 Months

-25.45%

6 Months

-71.53%

1 Year

-75.52%

2 Year

-75.52%

Key data

Stock price

$0.01

P/E Ratio

0.00

DAY RANGE

$0.01 - $0.01

EPS

-$0.03

52 WEEK RANGE

$0.01 - $0.04

52 WEEK CHANGE

-$75.52

MARKET CAP

1.017 M

YIELD

N/A

SHARES OUTSTANDING

42.372 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

N/A

BETA

0.00

PUBLIC FLOAT

N/A

AVERAGE 10 VOLUME

$141,004

AVERAGE 30 VOLUME

$77,959

Company detail

CEO: Shulman J. David
Region: US
Website: petrospharma.com
Employees: 20
IPO year: 2017

Issue type:
Market: OTCM
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Petros Pharmaceuticals, Inc. is based in New York, New York. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED) It also develops and commercializes H100, a patented topical formulation candidate for the. treatment of acute Peyronie's disease.

PTPI - Petros Pharmaceuticals Inc